Oncology Highlights - June 2019
Astrocytes play role immunosuppression, TILs related to spatial distribution, FDA and EMA approvals, ASCO guidelines
Oncology Highlights - May 2019
CRISPR FIH trial, Neo-neurogenesis in prostate cancer, CTC prospecting with HydroSeq (scRNA-seq), Industry updates, EMA and FDA approvals in May
Oncology Highlights - April 2019
TAMs' role in cancer, zebrafish model for drug selection, M&A in April, EMA and FDA approvals in April
Oncology Highlights - March 2019
Brain-on-a-chip, upcoming CAR-T therapies, Flagship Pioneering, Tecentriq approval for SCLC and TNBC
Oncology Highlights - February 2019
The Human Tumor Atlas Network (HTAN), barcoding single cells, FDA&EMA approvals, M&A oncology in February
AACR 2019 - Forward and reverse translational era
When most people think of the city of Atlanta (Georgia, USA), they think about Coca Cola, the Olympic stadium, or perhaps the Delta Airlines hub. But last week (29 March - 3 April 2019), this southern city was home to more than...
The growing challenge of handling multistream data capture in clinical trials - ACDM 2019
This year's annual conference of the Association for Clinical Data Management (ACDM) took place in Amsterdam. During a two-day event, the emphasis was on the growing challenges of multistream data capture in clinical trials, wi...
SMS-oncology sets out to improve patient recruitment for clinical trials
Drug development crucially relies on accurately designed and well recruiting clinical trials. However, low accrual rates of clinical trials and unmet recruitment targets have been global attention points for many years. A 70-80...
EMA & FDA Anti-cancer Drugs Recommendations for Approval in 2018
In 2018, EMA and FDA made a total of 44 positive recommendations for anti-cancer medicines to receive marketing approval.
ESMO 2018: Immunotherapy and other stories
ESMO 2018: Immunotherapy and other stories The annual European Society for Medical Oncology (ESMO) 2018 Congress took place from 19-23 October 2018 in breathtaking Munich, Germany. Held under the tagline "Securing access to op...